RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $47
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.